On Thursday, Shares of Apple Inc. (NASDAQ:AAPL), lost -0.58% to $129.36.
Apple, declared Apple Watch™ will be accessible in Italy, Mexico, Singapore, South Korea, Spain, Switzerland and Taiwan starting Friday, June 26 from the Apple Online Store (www.apple.com), Apple’s retail stores and select Apple Authorized Resellers.
Apple Watch, Apple’s most personal device yet, is an incredibly accurate timepiece, an intimate and immediate communication device and a groundbreaking health and fitness companion. Highly customizable for personal expression, Apple Watch also brings an entirely new way to receive information at a glance and interact with the world through third-party app experiences designed specifically for the wrist.
Apple Watch introduces revolutionary technologies counting the Digital Crown™, an innovative way to scroll, zoom and navigate fluidly without obstructing the display. The Retina® display with Force Touch on Apple Watch senses the difference between a tap and a press, providing a new way to quickly and easily access relevant controls. The Taptic Engine™ discreetly delivers a gentle tap on your wrist whenever you receive a notification or message.
Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, watches, and portable digital music players worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications.
Shares of AbbVie Inc. (NYSE:ABBV), inclined 0.61% to $67.42, during its last trading session.
Pharmacyclics LLC, an AbbVie company, declared that ibrutinib (IMBRUVICA®) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints counting overall survival (OS) and overall response rate (ORR) in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL, respectively) in the final analysis of the Phase III RESONATE™-2 (PCYC-1115) trial. RESONATE-2 is a randomized, multi-center, open-label study assessing the use of ibrutinib as compared to chlorambucil in treatment-naïve CLL/SLL patients aged 65 years or older. This is the first head-to-head trial in the clinical program that evaluates the safety and efficacy of ibrutinib as compared to traditional chemotherapy. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.
RESONATE-2 is a Pharmacyclics-sponsored trial and its protocol and specific performance aims were established in a special protocol assessment (SPA) with the U.S. Food and Drug Administration (FDA). A SPA is a contract with the FDA that an ongoing Phase III clinical trial design, its clinical endpoints, and other statistical analyses are acceptable to the Agency to support an approval. The trial enrolled 269 patients with CLL/SLL aged 65 years or older without preceding treatment in the U.S., EU and other regions. CLL patients with deletion of the short arm of chromosome 17 (del 17p CLL) were excluded from the trial since single-agent chlorambucil is not an effective therapy in this population. Patients were randomized to receive either ibrutinib 420 mg orally, once daily until progression or toxicity or chlorambucil on days 1 and 15 of each 28-day cycle for up to 12 cycles. The starting dose for chlorambucil in Cycle 1 was 0.5 mg/kg and was raised based on tolerability in Cycle 2 by increments of 0.1 mg/kg to a maximum of 0.8 mg/kg. The primary endpoint of the study was PFS as assessed by an Independent Review Committee according to the International Workshop on Chronic Lymphocytic Leukemia (iWCLL) 2008 criteria, with modification for treatment-related lymphocytosis. Key secondary endpoints comprised of ORR, OS, and safety.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases.
At the end of Thursday’s trade, Shares of Mindray Medical International Limited (NYSE:MR), gained 10.92% to $30.47.
Mindray Medical International Limited, declared that its board of directors (the “Board”) has received a preliminary non-binding proposal letter dated June 4, 2015 from Mr. Li Xiting, its Executive Chairman of the Board, President and Co-Chief Executive Officer, Mr. Xu Hang, its Chairman of the Board, and Mr. Cheng Minghe, its Co-Chief Executive Officer and Chief Planned Officerto acquire all of the outstanding shares of the Company not already owned by the Buyer Group in a going private transaction for US$ 30.0 per American Depositary Share (“ADS”, each ADS representing one ordinary share) or US$ 30.0 per ordinary share in cash, subject to certain conditions. A copy of the proposal letter is attached hereto as Exhibit A.
The Board intends to form a special committee comprising of independent directors to consider this proposal. The Company cautions its shareholders and others considering trading in its securities that the Board just received the non-binding proposal and has not made any decisions with respect thereto. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated.
Mindray Medical International Limited develops, manufactures, and markets medical devices worldwide. The company operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems.
Finally, Goldcorp Inc. (NYSE:GG), ended its last trade with -0.85% loss, and closed at $17.60, as the price of the precious metal falls following data showing requests for jobless benefits fell for the week ended May 30.
For the final week in May 276,000 people had applied for unemployment benefits, a decline of 8,000 contrast to the previous week, MarketWatch reports.
The data comes ahead of Friday’s jobs report, which is predictable to be strong and reinforce expectations that the Fed will move to enhance interest rates sooner rather than later. This could be a problem for gold as it doesn’t bear interest, MarketWatch added.
Goldcorp Inc. engages in the acquisition, exploration, development, and operation of precious metal properties in Canada, the United States, Mexico, and Central and South America. The company primarily explores for gold, silver, copper, lead, and zinc deposits.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
